Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Sema4 Closes Acquisition of Genomic Testing Specialist GeneDx.

Document Cited in Related
Vincent

MANews-(C)2009-2022

US-based genomic and clinical data intelligence platform company Sema4 (NASDAQ: SMFR) has completed the acquisition of GeneDx, LLC, a specialist in genomic testing and analysis for rare disorders, from Opko Health, Inc. (NASDAQ: OPK), the company said.

The transaction establishes Sema4 as one of the largest providers of genomic testing in the US and further strengthens its health information database to transform patient care and improve therapeutic development.

The acquisition accelerates Sema4's ability to deliver precision medicine while driving efficiency in its platform.

Sema4 has streamlined its management team to enable focused execution across its top business priorities, including expanded molecular testing and data-driven health system and biopharma partnerships.

Katherine Stueland, former president and CEO of GeneDx and former chief commercial officer of Invitae, will serve as Sema4's CEO and will serve on Sema4's board of directors.

Eric Schadt, PhD, Sema4's founder, will serve as president and chief research and development officer, reporting to Stueland, and will continue to serve on the board of directors.

Under the terms of the agreement, Sema4 has acquired GeneDx for an upfront payment of USD 150m in cash...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT